Skip to main content
Fig. 6 | The Journal of Headache and Pain

Fig. 6

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

Fig. 6

Galcanezumab effects on incidence of headache after occurrence of premonitory symptoms in responders and non-responders. A Incidence of all premonitory symptoms that were followed by headache decrease by the galcanezumab treatment in both, responders and non-responders. Note that after occurrence of premonitory symptoms, responders experienced significantly less headaches than non-responders (p = 0.004, DF = 1, Fisher exact). B Incidences of headache following occurrence of each of the 9 most common premonitory symptoms (i.e., premonitory symptoms that prior to treatment were followed by headache in > 20% of all patients) during the 3-month treatment period. The 100% (in A and B) represents incidences of all (A) and individual (B) premonitory symptoms that were followed by headache prior to treatment initiation

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us